ReviewCurrent obesity reports2026
Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.
Review in Current obesity reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of the reviewObesity represents a major global health challenge associated with substantial metabolic, cardiovascular, and oncologic risk. Recent advances in anti-obesity pharmacotherapies, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist, have redefined clinical management by enabling unprecedented weight loss and significant cardiometabolic benefits. This review summarizes current evidence on how incretin-based therapies affect body composition, eating behavior, and long-term weight trajectories, with a focus on the need for nutritional strategies that support lean mass preservation and durable lifestyle changes. RECENT
findingsAlthough incretin-based therapied effectively reduce body weight, the resulting weight loss includes a decline in fat-free mass, raising potential concerns about skeletal muscle preservation, particularly in vulnerable populations. Protein-enriched meal replacements (MRs) and structured dietary programs, including very low energy ketogenic therapy (VLEKT), have emerged as practical approaches to improve adherence, enhance fat loss, and stimulate muscle protein synthesis during medication-induced caloric restriction. Several studies indicate that MR-based interventions achieve greater weight loss and metabolic improvements than conventional diets, and that EAA-enriched formulations may provide additional advantages for preserving muscle mass. Combining MRs or VLEKT with incretin-based treatments may offer synergistic advantages by coupling pharmacological appetite regulation with controlled nutrient delivery and behavioral support. Structured nutritional interventions remain essential throughout pharmacotherapy and represent valuable alternatives when medications are discontinued or contraindicated. Overall, integrating incretin-based pharmacotherapy with optimized dietary strategies constitutes an approach to care that may enhance long-term effectiveness, promote nutritional rehabilitation, preserve muscle health, and address the needs of individuals at risk of sarcopenia.
Indexed as
Identifiers
41733759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.